Lilly Moves Closer To NDA Filing For RET Inhibitor In NSCLC

 
• By Joseph Haas
  
DNA strand and Cancer Cell Oncology Research Concept 3D rendering - Illustration
Lilly is developing Loxo's technology to target cancer on a genetic basis
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business